ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 1965

Autoantibodies Against a Specific 25-mer Peptide from P. Gingivalis Are Present in Sera of Patients with Rheumatoid Arthritis and Early Arthritis

Hsin-Yi Peng1, Ting-Yin Xue1, Fei-Hung Hsieh1, Yi-Ko Chen1, Mei-Chin Yin2, Che-Yi Chao2, Shu-Yao Tsai2, Chung-Ping Lin3, Po-Hao Huang3, Chien-Chung Huang3, Jiunn-Horng Chen3, Chung-Ming Huang3, Der-Yuan Chen4, Joung-Liang Lan5 and Gregory Tsay3, 1China Medical University, Taichung, Taiwan, 2Asia University, Taichung, Taiwan, 3China Medical University Hospital, Taichung, Taiwan, 4China Medical University Hospital Rheumatology and Immunology Center, Taichung, Taiwan, 5China Medoical University Hospital, Taichung, Taiwan

Meeting: ACR Convergence 2022

Keywords: , , ,

Session Information

Date: Monday, November 14, 2022

Session Title: RA – Diagnosis, Manifestations, and Outcomes Poster IV

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: The presence of rheumatoid factor (RF) or anti-cyclic citrullinated protein/peptide antibodies (ACPA) are included in the 2010 the ACR/EULAR classification criteria of rheumatoid arthritis (RA). But the prevalence of RF and ACPA in the RA population was lower than 60%. The development of a new detection assay with increasing the sensitivity for the diagnosis of RA is needed.

Methods: A 25-peptide named BR1 from the cysteine protease of Porphyromonas gingivalis was synthesized for the study. Serum samples from patients with RA, early arthritis, other rheumatic diseases, and normal controls were used in the study. The anti-peptide antibodies were detected by ELISA.

Results: Anti-BR1 were detected in 56.0% (59/106) of RA patients and were found in 63.8% (23/36) of RA patients without both RF and/or ACPA. The serological positive rates with the two tests of RF and ACPA and with the three tests of anti-BR1, RF, and ACPA were 66% and 84.2%, respectively. The positive rates Anti-BR1 were detected in 60.0% (9/15) of patients with early arthritis, but neither RF nor ACPA was detected in this group of patients. The sensitivity and specificity for RA were 60.1% and 95%, respectively.

Conclusion: A specific 25-mer peptide from the cysteine protease of P. gingivalis is the epitope for humoral immune response in rheumatoid arthritis. The anti-25-mer peptide antibody test is an excellent new test for the diagnosis of patients with RA and early arthritis.

Disclosures: H. Peng, None; T. Xue, None; F. Hsieh, None; Y. Chen, None; M. Yin, None; C. Chao, None; S. Tsai, None; C. Lin, None; P. Huang, None; C. Huang, None; J. Chen, None; C. Huang, None; D. Chen, None; J. Lan, None; G. Tsay, None.

To cite this abstract in AMA style:

Peng H, Xue T, Hsieh F, Chen Y, Yin M, Chao C, Tsai S, Lin C, Huang P, Huang C, Chen J, Huang C, Chen D, Lan J, Tsay G. Autoantibodies Against a Specific 25-mer Peptide from P. Gingivalis Are Present in Sera of Patients with Rheumatoid Arthritis and Early Arthritis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/autoantibodies-against-a-specific-25-mer-peptide-from-p-gingivalis-are-present-in-sera-of-patients-with-rheumatoid-arthritis-and-early-arthritis/. Accessed March 23, 2023.

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/autoantibodies-against-a-specific-25-mer-peptide-from-p-gingivalis-are-present-in-sera-of-patients-with-rheumatoid-arthritis-and-early-arthritis/